DEPLOYDatabase

Deployment

Senhance at United States

Asensus Surgical, formerly TransEnterix and based in Durham, North Carolina, was a public company on the NYSE American as ASXC that made the Senhance multi-port laparoscopic robotic system, FDA-cleared via 510(k) in October 2017 with subsequent instrument and indication clearances, making Senhance a genuinely cleared if relatively low-volume commercial product. The headline current-state fact is that Karl Storz acquired the company, closing on August 22, 2024 at $0.35 per share for about $95 million, a roughly 67 percent premium, with the stock ceasing to trade on the NYSE American at close, leaving Asensus a private Karl Storz subsidiary; this is the canonical example of a large medtech company absorbing a struggling robotics startup for a fraction of its historic enterprise value. The registry records Senhance at commercial maturity with an active lifecycle, since it remains a cleared product line continuing under Karl Storz, while the company status is recorded as acquired. The company's next-generation LUNA system, unveiled in February 2023 with claimed real-time clinical intelligence and cloud machine learning, was not FDA-submitted, not cleared, and not for sale as of the August 2024 close, so LUNA is recorded at research maturity, with a 2025 FDA target that is unverified as met and a current status under private ownership that is not publicly traceable. On AI substance the cleared digital-surgery features are machine-vision and digital-laparoscopy assists that are real but incremental rather than autonomy, and the Performance-Guided Surgery framing was oversold relative to what is cleared.

Senhance by Asensus Surgical · Catalog entry · 6 sources · not yet field-verified · Surgical robots

Track Senhance at United States

Recent coverage

See all coverage →

Machine-readable surfaces

Footage

PRIMARY SOURCE
Courtesy of Asensus Surgical

Asensus Surgical footage of its Senhance digital-laparoscopy system in a simulation and training environment (not a live clinical case). A surgeon-teleoperated system, not autonomous.

The Senhance system received FDA 510(k) clearance in 2017 for laparoscopic procedures and pediatric clearance in March 2023, with limited US adoption across approximately 5 or more hospitals. Reported US sites include Mayo Clinic, which conducted first pediatric cases in 2023, and Rocky Mountain Hospital for Children in Denver in July 2024; parent company Asensus filed for Chapter 11 bankruptcy in March 2025 with operations continuing under restructuring.

Key facts

FDA 510(k)
Cleared 2017 for laparoscopic procedures
US sites
~5+ hospitals (limited adoption)
Parent financial status
Asensus filed for Chapter 11 bankruptcy March 2025; operations continuing under restructuring

Safety record

No incidents on record for Senhance at United States.

Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.

Trust tier
Catalog entry · 6 sources · not yet field-verifiedhow tiers work →
Last updated
2026-06-29
Model
Senhance
Company
Asensus Surgical
Location
United States
Status
operational
First seen
2017-01-01
ID
29c1912a-a66e-48b9-9c37-e8bc4d9d5b16

Timeline

  1. Jan 2017
    First recorded
    Senhance first documented operating at United States.
  2. Jan 2017
    created
  3. Jun 2026
    Current status: operational, reviewed
    Latest recorded state. New status transitions append here as the deployment-status recorder produces them.

On the deployment map

Senhance operates in United States. Explore the full verified map:

Sources (6)

  1. https://www.asensus.com/investors
  2. https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001576493&type=8-K
  3. https://ir.asensus.com/news-releases/news-release-details/asensus-surgical-announces-leading-united-states-based-hospital
  4. https://www.sec.gov/Archives/edgar/data/876378/000143774923026249/asxc20230918_8k.htm
  5. https://ir.asensus.com/news-releases/news-release-details/asensus-surgical-announces-rocky-mountain-hospital-children
  6. https://ir.asensus.com/news-releases/news-release-details/asensus-surgical-receives-fda-510k-clearance-pediatric
Methodology: Verified · 6 sources (5 primary) · last reviewed 2026-06-29

Verification posture

Verified

High confidence

Review state

Stable

Last reviewed 2026-06-29

Maturity + lifecycle

Maturity stage: commercial

Lifecycle: active

Architectural position

Cohort: surgical

Sources by quality tier

3
primary-company-ir
Company IR disclosure
2
primary-sec-filing
SEC filing
1
unclassified
Unclassified source

The framework is documented at /methodology. Corrections at /corrections. Reviewer: DEPLOY editorial team.

Methodology surface for Senhance at United States.

Common questions

What is the Senhance deployment at United States?
Senhance, built by Asensus Surgical, is recorded as a deployment at United States on the DEPLOY registry. Asensus Surgical operates the deployment directly.
Who operates Senhance at United States?
Asensus Surgical, the manufacturer of Senhance, operates this deployment directly. This is a maker-deploys-its-own-product arrangement rather than a customer pilot.
When did the Senhance deployment at United States go live?
The deployment is recorded as starting January 1, 2017 on the DEPLOY registry. Earlier activity may exist but is not yet sourced.
Have there been incidents at the Senhance deployment at United States?
No active incidents affecting this deployment are recorded on the DEPLOY registry. Absence of recorded incidents is not a guarantee no incident occurred; DEPLOY records only sourced incidents and suppresses retracted ones.

Deploy Watch

Track this deployment.

We notify you when status changes against primary-source evidence, contract events surface, or a related incident is filed.